The Directorate General of Foreign Trade (DGFT) has announced amendments to the Standard Input Output Norms (SION) for the export of erythromycin stearate tablets. The revision, detailed in a Public Notice issued by DGFT Director General Santosh Kumar Sarangi, was published in the Gazette of India Extraordinary and is expected to streamline export processes for pharmaceutical manufacturers.

Key Highlights:
Revised SION for Erythromycin Stearate Tablets:

• Each 250 mg erythromycin stearate tablet will now require 334 mg of erythromycin stearate as an import input.

• Norms for other tablet variants can be calculated on a pro-rata basis.

Objective of the Amendment:

• The updated norms aim to enhance compliance and improve trade efficiency for pharmaceutical exporters.

• The revision aligns with the evolving needs of the pharmaceutical industry to facilitate smoother export operations.

Understanding SION:

• SION stands for Standard Input Output Norms, which describes the amount of input materials required to manufacture a particular export product.

• DGFT periodically updates SION to bring about changes in the industry norms and to help issue Advance Licenses to the exporters.

Direct Applicability:

• The new amendment comes into force immediately and is applicable to all the present and future exports of erythromycin stearate tablets.

• Issued under the powers conferred by paragraphs 1.03 and 2.04 of the FTP 2023.

Statements from Leaders or Officials:
Santosh Kumar Sarangi, Director General of Foreign Trade:
“The amendment in SION A-222 will streamline export norms, ensuring better compliance and efficiency in trade. This modification aligns with the evolving needs of the pharmaceutical industry and aims to facilitate smoother trade operations for exporters.”The amended SION norms for erythromycin stearate tablets are expected to benefit pharmaceutical exporters by providing clearer guidelines on input requirements, reducing the need for repeated approvals from the DGFT headquarters. This move is part of the government’s broader efforts to simplify export processes and enhance India’s pharmaceutical trade competitiveness.